Accessibility Menu
Raphael Pharmaceutical logo

Raphael Pharmaceutical(OTC) RAPH

Market Cap$28.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-36%
5 YearN/A
1 Year+87%
1 Month+0%
$1.40
+0.00%
+0.00Today
Raphael Pharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 1.402026-07-28
Raphael Pharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 1.402026-07-20
1 month+0%USD 1.402026-05-21
3 month+0%USD 1.402026-04-29
Year to date+0%USD 1.402025-12-31
1 year+86.67%USD 0.752025-07-08
3 year-16.17%USD 1.672023-07-13
Since inception-36.36%USD 2.202023-01-05

Raphael Pharmaceutical Financials at a Glance

Market Cap

$28.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.08M

EPS (TTM)

-$0.05

P/E Ratio

-25.69

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.40

Volume

228

Open

$1.40

Previous Close

$1.40

Daily Range

$1.40 - $1.40

52-Week Range

$0.04 - $1.40

Estimated Earnings Date

N/A

RAPH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Raphael Pharmaceutical

Raphael develops cannabinoid-based therapies for autoimmune diseases like rheumatoid arthritis. Its products aim to help people manage chronic inflammation and related symptoms. The company also offers a dietary supplement for joint health support.

What’s in the Medicine Cabinet?

  • Pharmaceutical Candidates: Cannabinoid-based drugs for autoimmune and inflammatory diseases; 0% of revenue (pre-revenue).
  • RaphaWell Supplement: Plant-based dietary supplement for rheumatoid arthritis support; 0% of revenue (pre-revenue).
  • Pipeline Products: Preclinical candidates for asthma and COVID-19-related inflammation; 0% of revenue.

Growth and Expansion: The Road So Far

  • Launched RaphaWell supplement in the U.S. in August 2025.
  • Completed proof-of-concept clinical study for rheumatoid arthritis in December 2024.
  • Filed provisional patent for cannabinoid technology in November 2025.
  • Extended research partnership with Rambam Med-Tech in 2025.
  • Secured exclusive CBD oil supply agreement with Way of Life Cannabis in 2020.

What Makes Raphael Stand Out?

Raphael operates as a virtual company, outsourcing all research and manufacturing. Its focus is on cannabinoid-based therapies for immune system disorders. The company leverages partnerships for research, supply, and intellectual property development.

Five Things You Need to Know

  • No revenue in 2025 or 2024; company remains pre-revenue.
  • Operating loss was $1.25 million in 2025, down 17.5% from 2024.
  • Cash position was $45,000 as of December 31, 2025.
  • Negative working capital of $1.44 million at year-end 2025.
  • No full-time employees; all operations outsourced to third parties.

Bottom Line

Raphael is an early-stage drug developer focused on cannabinoid therapies for autoimmune diseases. The company relies on partnerships and remains pre-revenue as of 2025.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Shlomo Pilo

Website

www.raphaelpharmaceutical.com

Headquarters

Jaffa, TA 6803605, IL

RAPH Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

79.82%

Return on Capital

N/A

Return on Assets

-35966.67%

Earnings Yield

-3.89%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$28.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

20.18M

Volume

228

Avg. Volume

7.333

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.04M

EBITDA

-$1.04M

Operating Cash Flow

-$45.00K

Capital Expenditure

$0.00

Free Cash Flow

-$45.00K

Cash & ST Invst.

$1.00K

Total Debt

$37.00K

Raphael Pharmaceutical Performance Analysis

Raphael Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Raphael Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Raphael Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.23119.5%
20232023-12-31USD -0.08-65.7%
20242024-12-31USD -0.081.1%
20252025-12-31USD -0.07-19.6%
Raphael Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3025.1%
Q32025-09-3020.7%
Q42025-12-31-5.4%
Q12026-03-3116.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$28.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$229.00K

+46.6%

EBITDA

-$223.00K

+47.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.00K

-98.0%

Total Debt

$37.00K

-9.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$37.00K

-9.8%

Return on Assets

-359.67%

N/A

Return on Invested Capital

62.76%

N/A

Free Cash Flow

-$44.00K

+78.9%

Operating Cash Flow

-$44.00K

+78.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GBLPGlobal Pharmatech, Inc.
$0.08+0.00%
MEDIFMediPharm Labs Corp.
$0.05-2.23%
EMITFElbit Imaging Ltd.
$1.60+0.00%
MYCOFNoveris Health Sciences Inc.
$0.73+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$110.08+0.02%
NVDANvidia
$220.55+0.01%
SOUNSoundHound AI
$7.07+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.64-0.02%

Questions About RAPH

What is the current price of Raphael Pharmaceutical?

Raphael Pharmaceutical is trading at $1.40 per share.

What is the 52-week range for Raphael Pharmaceutical?

Over the past 52 weeks, Raphael Pharmaceutical has traded between $0.04 and $1.40.

How much debt does Raphael Pharmaceutical have?

As of the most recent reporting period, Raphael Pharmaceutical reported total debt of $37.00K.

How much cash does Raphael Pharmaceutical have on hand?

Raphael Pharmaceutical reported $1.00K in cash and cash equivalents in its most recent financial results.

What is Raphael Pharmaceutical’s dividend yield?

Raphael Pharmaceutical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services